USANA Health Sciences Inc. - 10-K Summary (Fiscal Year Ended Jan 3, 2004)
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended January 3, 2004 (a 53-week year). USANA Health Sciences, Inc. is a Utah corporation that develops, manufactures, and distributes nutritional and personal care products through a network marketing system. The company operates two reportable segments: Direct Selling (nutritional and personal care products sold via independent "Associates" and "Preferred Customers") and Contract Manufacturing (added in 2003 via the acquisition of Wasatch Product Development, Inc.). As of the reporting date, USANA had approximately 88,000 active Associates and 51,000 active Preferred Customers globally.
Key Financial Metrics
| Metric | Fiscal 2003 | Fiscal 2002 |
|---|---|---|
| Net Sales | $200.0 million | $133.8 million |
| Gross Profit | $155.6 million (77.8% margin) | $100.4 million (75.0% margin) |
| Net Earnings | $20.8 million | $8.5 million |
| Diluted EPS | $0.98 | $0.41 |
| Cash and Equivalents | $19.0 million | $6.7 million |
| Working Capital | $18.3 million | $1.2 million |
| Long-Term Debt | $0 | $2.6 million |
| Associate Incentives | $78.7 million (39.3% of sales) | $51.2 million (38.3% of sales) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 49.5% year-over-year, driven by a 48.1% increase in the Direct Selling segment and the addition of the Contract Manufacturing segment ($1.8 million contribution).
- Profitability: Net earnings more than doubled, rising from $8.5 million to $20.8 million. Gross margin improved to 77.8% due to cost improvements and pricing changes.
- Debt Elimination: The company retired all outstanding long-term debt during the first quarter of 2003, resulting in zero long-term debt as of January 3, 2004.
- Acquisitions: Completed the acquisition of Wasatch Product Development, Inc. (WPD) for $5.3 million in July 2003, establishing the Contract Manufacturing segment.
- Stock Split: Executed a two-for-one stock split in October 2003; all share data in this report is adjusted to reflect the split.
Guidance, Outlook, and Risks
- Guidance: Management expects annual net sales for fiscal year 2004 to range between $245 million and $255 million.
- Expansion: Operations launched in Mexico in March 2004. New markets in South Korea and Singapore were entered in 2003.
- Raw Material Risks: A temporary global shortage of Coenzyme Q10 (CoQ10) is expected to increase raw material costs and negatively impact gross margins for affected products until mid-2004.
- Regulatory Risks: The Japanese government temporarily held shipments of products containing gelatin due to Bovine Spongiform Encephalopathy (BSE) concerns, though USANA asserts its gelatin source is safe. The company faces ongoing regulatory scrutiny regarding network marketing practices and product claims (FTC/FDA).
- Market Risk: Approximately 53.7% of net sales in 2003 were generated outside the U.S., exposing the company to foreign currency exchange rate fluctuations.
Investor Verification Checklist
- Associate Retention: Verify the sustainability of the 33.3% growth in active Associates and the impact of high turnover rates on future revenue.
- CoQ10 Impact: Monitor gross margin trends in Q2 and Q3 2004 to assess the financial impact of the CoQ10 shortage and price increases.
- Regulatory Compliance: Review any updates regarding the Japanese gelatin shipment hold and potential FTC actions regarding network marketing compensation plans.
- Debt-Free Status: Confirm the company maintains its debt-free balance sheet and sufficient liquidity ($19M cash) to fund international expansion without new financing.
- Stock Repurchases: Track the execution of the authorized $10 million share repurchase program, noting $8.2 million was spent in 2003.